UBX News and Press, Unity Biotechnology Inc.

2024-04-15 11:52:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unity Biotechnology (NASDAQ: UBX ) just reported results for the fourth quarter of 2023. Unity Biotechnology reported earnings per share of -28 cents. This was above the a...

2024-04-15 07:10:51 ET More on Unity Biotechnology Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data for Unity Biotechnology Financial information for Unity Biotechnology Read the full article on Seeking Alpha For fur...

SOUTH SAN FRANCISCO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 202...

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...

Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...

2024-03-11 05:50:46 ET More on related stocks: Oracle Q3 Earnings Preview: Cloud Computing Business In Focus Blink Charging: EV Tailwinds Offer A Path To Profitability In 2025 Ulta Beauty: We Are Not Adding To Our Position Before The Earnings Release (Rating Downgrad...

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced new research published in the peer-reviewed journal Nat...

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the first patients have been dosed in the Phase 2 ASPIR...

2023-12-06 17:40:37 ET More on Unity Biotechnology Wedbush upgrades Unity Biotechnology to outperform, cites cash runway Unity Biotechnology GAAP EPS of -$1.05 misses by $0.16 Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data...

2023-11-16 13:09:59 ET More on Unity Biotechnology Unity Biotechnology GAAP EPS of -$1.05 misses by $0.16 UNITY Biotechnology to exercise warrants for $4.38M in gross proceeds Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data...